Lapeer · Rochester Hills · Telehealth

Menopause Care Program Structured management for every stage of the transition.

Hot flashes, night sweats, sleep disruption, vaginal changes, mood shifts, bone loss — menopause affects every system. Dr. Andrei provides structured, ongoing menopause care that addresses the full symptom picture with hormone therapy, non-hormonal options, and long-term monitoring.

The menopause care program is not a single appointment. It is an ongoing clinical relationship — with the same physician, at every visit, who knows your history and adjusts your care as the transition evolves.

Board-certified gynecology care  ·  Most major insurances accepted
GYN-only practice serving Lapeer County & Oakland County

Program
Menopause Care Program
Setting
In-Person · Telehealth Available
Includes
HRT · Symptom Management · Monitoring
Visit Frequency
Every 3–6 Months Initially
Coverage
Most Major Insurances
Ongoing Care Programs

Menopause Care — Structured Management for Every Stage of the Transition

Menopause is not a single event — it is a transition that unfolds over years, with a symptom burden that varies widely from one woman to the next. Some women move through perimenopause with minimal disruption. Others experience hot flashes, sleep loss, mood changes, vaginal atrophy, cognitive shifts, and joint pain that significantly affect quality of life and long-term health. Both experiences deserve the same level of clinical attention.

At Lapeer Women’s Health, Dr. Andrei provides a structured menopause care program — not a one-time conversation about hormone therapy options, but an ongoing clinical relationship that begins during the perimenopausal transition and continues through postmenopause. The program includes symptom evaluation, hormone therapy initiation and monitoring, vaginal and sexual health management, bone health assessment, and cardiovascular risk context.

Treatment decisions are individualized. Not every woman is a candidate for hormone therapy — and not every woman who is a candidate wants it. Dr. Andrei discusses the full spectrum of options, from FDA-approved hormone therapy to non-hormonal prescription alternatives to evidence-based lifestyle interventions, and helps you make an informed decision based on your symptom burden, your health history, and your goals.

What the Program Covers

Menopause Care at LWH — What Each Visit Addresses

The menopause care program is built around your current stage of transition and your specific symptom picture. These are the clinical areas addressed across the program.

Vasomotor symptom management

Hot flashes and night sweats — the most common menopause symptoms — range from mildly inconvenient to severely disruptive. Dr. Andrei evaluates frequency, severity, and impact on sleep and daily function, and discusses hormone therapy and non-hormonal options including SSRIs, SNRIs, gabapentin, fezolinetant, and oxybutynin.

Hormone therapy initiation and management

Systemic estrogen — alone or combined with progesterone — is the most effective treatment for vasomotor symptoms and provides benefits for bone, cardiovascular, and vaginal health when started at the appropriate time. Dr. Andrei reviews your candidacy, selects the appropriate formulation and dose, and monitors your response at each follow-up visit.

Genitourinary syndrome of menopause (GSM)

Vaginal dryness, atrophy, painful intercourse, urinary urgency, and recurrent UTIs caused by estrogen decline — collectively called GSM — affect the majority of postmenopausal women and are highly treatable. Local vaginal estrogen, ospemifene, and DHEA (prasterone) are among the options Dr. Andrei discusses.

Sleep and mood management

Insomnia, anxiety, irritability, and low mood are common during the menopausal transition and are often driven by hormonal fluctuation and sleep disruption from night sweats. Dr. Andrei addresses these symptoms within the menopause care context — distinguishing hormonal contributors from independent mood disorder when indicated.

Bone health and osteoporosis prevention

Estrogen withdrawal accelerates bone loss in the years immediately following menopause. Dr. Andrei reviews DEXA scan results, fracture risk, calcium and vitamin D status, and the role of hormone therapy and other medications in preserving bone density. See also: Bone Health Counseling.

Cardiovascular and metabolic context

Estrogen loss changes cardiovascular risk profile — affecting lipid metabolism, blood pressure, insulin sensitivity, and body fat distribution. Dr. Andrei addresses the cardiovascular context of menopause management and coordinates with primary care for metabolic monitoring when indicated.

The Menopause Timing Principle

The Window of Opportunity — Why Timing Matters in Menopause Care

The evidence supporting hormone therapy is strongest when treatment is initiated within 10 years of menopause or before age 60 — the “timing hypothesis” or “window of opportunity.” Dr. Andrei discusses this clinical evidence with every patient considering hormone therapy.

  • Hormone therapy started early in the menopausal transition provides the greatest symptom relief and the most favorable long-term benefit-to-risk ratio
  • Cardiovascular protective effects of estrogen are most pronounced when initiated close to menopause — not years later
  • Bone-protective effects begin immediately and are most effective when bone loss is still in early stages
  • Women who delay hormone therapy by years due to fear or misinformation may lose the window for optimal benefit
  • The Women’s Health Initiative findings are frequently misapplied — Dr. Andrei reviews the actual data, not the headlines
  • Not every woman is a candidate — contraindications are reviewed individually, not applied by formula

“Menopause care has been shaped by decades of fear around hormone therapy — fear that was never fully supported by the evidence and that has caused enormous unnecessary suffering. My job is to give every patient the actual information, the actual data, and the space to make the decision that is right for her.”

— Dr. Ramona D. Andrei · MD, PhD, FACOG
  • Initial menopause visit: full symptom assessment, hormone candidacy review, treatment options discussion
  • Follow-up at 6–12 weeks after initiating hormone therapy to assess response and adjust dose
  • Ongoing visits every 3–6 months during the management phase, annually once stable
  • Telehealth available for follow-up visits and result reviews at the Rochester Hills office on Mondays
  • Lab monitoring coordinated at each visit — hormone levels, lipids, metabolic panel as indicated
Before Your Visit

Questions About the Menopause Care Program

Perimenopause is the transition phase leading up to menopause — characterized by irregular cycles, changing flow, and the onset of vasomotor and other symptoms. Menopause is defined as 12 consecutive months without a menstrual period. The average age of menopause in the United States is 51, but the perimenopausal transition can begin in the mid-40s or earlier. FSH and estradiol levels can support the clinical picture but are not always necessary to confirm the diagnosis. Dr. Andrei reviews your symptom pattern and cycle history to determine your stage at your first visit.
For most healthy women under 60 who are within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. Absolute contraindications include unexplained vaginal bleeding, active or recent breast cancer, active blood clot or clotting disorder, active liver disease, and known coronary artery disease. Dr. Andrei reviews your personal and family health history thoroughly before discussing hormone therapy candidacy — the decision is individualized, not formula-based.
Systemic hormone therapy — delivered by pill, patch, gel, spray, or ring — enters the bloodstream and treats both vasomotor symptoms and genitourinary symptoms throughout the body. Local vaginal estrogen — cream, tablet, insert, or ring — acts primarily on vaginal and urethral tissue with minimal systemic absorption and is used specifically for GSM symptoms (vaginal dryness, atrophy, painful intercourse, recurrent UTIs). Local vaginal estrogen is safe for most women, including many who are not candidates for systemic therapy.
Non-hormonal options are available for every menopause symptom. For vasomotor symptoms: fezolinetant (Veozah), SSRIs and SNRIs (paroxetine, venlafaxine, desvenlafaxine), gabapentin, and oxybutynin all have evidence for hot flash reduction. For GSM: ospemifene (Osphena) and DHEA (Intrarosa/prasterone) are non-estrogen options. For bone health: bisphosphonates, RANK-L inhibitors, and other agents are effective independently of hormone therapy. Dr. Andrei reviews every option — hormonal and non-hormonal — at your visit.
There is no universal answer. Current guidance from NAMS (North American Menopause Society) supports continuing hormone therapy as long as the benefits outweigh the risks for the individual patient — and does not endorse an arbitrary 5-year cutoff. Many women benefit from longer-term therapy, particularly for bone protection and quality of life. Dr. Andrei reviews the ongoing benefit-risk balance at each annual visit and adjusts the plan accordingly.
Menopause Specialist
GYN-Only Practice
MD, PhD, FACOG
Board-Certified Gynecologist
HRT & Non-Hormonal
All Options Discussed
Telehealth Available
Follow-Up Visits
Start Your Menopause Care

Menopause Care That
Takes the Transition Seriously.

Structured menopause management with Dr. Andrei — vasomotor symptoms, hormone therapy, vaginal health, bone density, and long-term monitoring. The full picture, not just a prescription.

Lapeer Office
(810) 969-4670
Rochester Hills
(248) 923-3522

The information on this page is intended for educational purposes only and does not constitute medical advice. Individual symptoms, diagnoses, and treatment options vary significantly. Reading this content does not establish a physician-patient relationship with Dr. Ramona D. Andrei or Lapeer Women’s Health. If you are experiencing a medical emergency, call 911 or go to the nearest emergency room immediately. Please consult a qualified healthcare provider for advice specific to your situation. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.

Gynecologic care for women of every age

Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307

Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.